×
Tablets being processed in laboratory
Insights
September 22, 2026

6 Things to Look for in a Bile Acid CDMO

Choosing the right CDMO for bile acids is a more nuanced decision than selecting a general pharmaceutical contract manufacturer. Bile acid molecules are chemically complex, derived from regulated animal-sourced...

Image of ICE Pharma chemist working with Bile Acid
Insights
September 11, 2026

The History of Bile Acids: From Traditional Chinese Medicine to Modern Pharmaceuticals

The history of bile acids is a remarkable journey spanning more than two millennia, from the apothecary traditions of ancient China to the sophisticated pharmaceutical pipelines of the 21st...

Company HighlightsInsights
September 2, 2026

WEBINAR – Exploring New Formulation Possibilities with Bile Salts

Exploring New Formulation Possibilities with Bile Salts How can bile salts help overcome the challenges of poorly soluble compounds? Poor aqueous solubility remains one of the key challenges in...

Company HighlightsInsights
August 10, 2026

ICE Pharma Sites in Basaluzzo and Reggio Emilia Obtain Authorized Economic Operator (AEO) Status

ICE Pharma is pleased to announce that its Basaluzzo and Reggio Emilia sites have successfully obtained Authorized Economic Operator (AEO) status from the Italian Customs and Monopolies Agency (Agenzia...

Company HighlightsRaichem
May 4, 2026

Raichem Strengthens Community Support in Raichur with Clean Water and Food Initiatives

Reinforcing its commitment to corporate social responsibility and community welfare, Raichem has launched two impactful initiatives in Raichur, Karnataka, addressing critical challenges related to access to clean drinking water...

Company HighlightsRaichem
April 9, 2026

Corporate Social Responsibility in the Pharmaceutical Industry: Advancing Global Health Through Sustainable Impact

In the evolving landscape of the B2B pharmaceutical industry, companies are expected to deliver more than high-quality products and services. Today, corporate social responsibility (CSR) and ESG in pharma...

Company HighlightsICEJapan
February 2, 2026

Strengthening Sustainability Through Verified Carbon Footprint Certification

Our company has achieved ISO 14067 certification for Carbon Footprint verification, marking a significant milestone in our sustainability journey and reinforcing our commitment to responsible pharmaceutical manufacturing. With this...

Company HighlightsNZP
December 9, 2025

New Zealand Pharmaceuticals Achieves Recertification for ISO 14001, ISO 45001, ISO 14064-1, and ISO 50001

New Zealand Pharmaceuticals (NZP) has successfully completed its recertification and annual audits for four major international standards:ISO 14001 (Environmental Management), ISO 45001 (Health & Safety Management), ISO 14064-1 (Greenhouse...

ArticlesCompany Highlights
September 25, 2025

Bile Acids: A Promising Class of Functional Excipients in Modern Drug Delivery

We are proud to share our latest contribution to the field of specialty chemicals, where we explore the promising role of bile acids (BAs) as functional excipients in drug...

Company HighlightsInsights
September 19, 2025

Basaluzzo Site Renews GMP Certification from AIFA Until 2028

We are proud to announce that the Basaluzzo site has successfully renewed its GMP (Good Manufacturing Practice) certification issued by AIFA, the Italian Medicines Agency. This renewed authorization is...

Company HighlightsRaichem
July 9, 2025

ICE Pharma Inaugurates New F Block at Raichem (India), Boosting UDCA Production from Chicken Bile

ICE Pharma is proud to announce the inauguration of the new F Block at Raichem, our subsidiary in India — a strategic investment aimed at expanding production capacity and...

ArticlesCompany Highlights
June 3, 2025

Improving Solubility and Bioavailability with Bile Acids

Can nature’s own surfactants unlock the next generation of drug delivery? In a new interview, ICE Pharma’s Chief Commercial Officer, Roger Viney, discusses how bile acids are transforming the...